Last reviewed · How we verify
Treatment with vismodegib
Vismodegib inhibits the Hedgehog signaling pathway by blocking Smoothened, a key transmembrane protein required for pathway activation.
Vismodegib inhibits the Hedgehog signaling pathway by blocking Smoothened, a key transmembrane protein required for pathway activation. Used for Locally advanced basal cell carcinoma, Metastatic basal cell carcinoma.
At a glance
| Generic name | Treatment with vismodegib |
|---|---|
| Sponsor | University Hospital, Bordeaux |
| Drug class | Hedgehog pathway inhibitor |
| Target | Smoothened (SMO) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Vismodegib is a small-molecule antagonist of Smoothened (SMO), a G-protein coupled receptor essential for Hedgehog pathway signaling. By blocking SMO, it prevents activation of downstream transcription factors (GLI1/GLI2) that drive proliferation in Hedgehog-dependent cancers. This mechanism is particularly effective in basal cell carcinoma, where aberrant Hedgehog signaling is a primary driver of tumorigenesis.
Approved indications
- Locally advanced basal cell carcinoma
- Metastatic basal cell carcinoma
Common side effects
- Muscle cramps
- Alopecia
- Dysgeusia (taste disturbance)
- Weight loss
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Vismodegib in Treating Patients With Advanced Chondrosarcomas (PHASE2)
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery (PHASE1)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas (PHASE2)
- Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (PHASE1)
- Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma (EARLY_PHASE1)
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment with vismodegib CI brief — competitive landscape report
- Treatment with vismodegib updates RSS · CI watch RSS
- University Hospital, Bordeaux portfolio CI